drugset
drugset / Trial / NCT00712062

Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma

NCT00712062 ↗

Phase 2 Withdrawn University of Florida
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if pemetrexed is effective in the treatment of primary central nervous system lymphoma (PCNSL) that has either worsened during treatment or has returned after completing treatment.

Timeline

Start
2009-02
Primary completion
2010-02
Completion
2010-02

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

primary central nervous system lymphoma